- ADVERTISEMENT
-
Most Popular
- ADVERTISEMENT
SNY
High-Level Measures for Earnings Momentum Make Sanofi (SNY) a Strong Buy
The current recommendation of Strong Buy for Sanofi SA (NYSE:SNY) is the result of using the stock evaluator from Portfolio Grader, which incorporates Louis Navellier's investing approach. SNY has maintained this ranking for 2 months.
Sanofi (SNY) a Strong Buy on Outstanding Quant Score
Sanofi SA (NYSE:SNY) is classified as a member of the 135 company Pharmaceuticals GICS industry group, which is a segment of the 783 company GICS Health Care sector. SNY's market value is $124.3 billion which falls in the top decile in its industry group. The stock's current Portfolio Grader score places it 2 among the 135 companies in this industry group, positioning it among the leaders; among the sector leaders with a ranking of 18 among the 783 companies in the sector, and number 194 in the nearly 5,000 company Portfolio Grader universe.
Analytics Keep Sanofi (SNY) Strong Buy Ranking
Currently, Sanofi SA (NYSE:SNY) has a Strong Buy using the stock evaluator from Portfolio Grader, which incorporates Louis Navellier's investing approach. This represents no change from the previous week and is the same ranking SNY has had from Portfolio Grader for the last month.
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Soars on Drug Breakthrough
Alnylam Pharmaceuticals (ALNY) shares skyrocketed more than 50% on Wednesday morning on the news that the company's latest drug impressed.
After Johnson & Johnson (JNJ) Earnings Fail, Buy These Pharma Stocks Instead (RHHBY, SNY)
Shares of Johnson & Johnson slid in trading Tuesday after first-quarter earnings results disappointed. Here's where to turn in pharma today
3 Stocks to Watch on Monday: Tesla Inc (TSLA), Sanofi SA (ADR) (SNY) and Imagination Technologies Group plc (IMG)
Tesla (TSLA) beats estimates for Q1 deliveries, a Sanofi (SNY) drug delivers and Imagination Technologies (IMG) craters more than 60%.
Flexion Therapeutics Inc (FLXN) Stock Soars on Possible Sale to Sanofi
Flexion (FLXN) may soon be acquiring Sanofi (SNY) to boost its arthritis medications portfolio. Here's what you should know about the deal.
Amgen, Inc. (AMGN) Q4 Earnings Preview
Amgen (AMGN) reports Q4 earnings on Thursday, and if something does weigh on AMGN stock, it'll likely be one of these three factors.
Amgen, Inc.: Capture Stronger Upside in AMGN Stock
Uncertainty, optimism and good liquidity are good reasons to consider an Amgen spread in lieu of AMGN stock in front of earnings.
The Top 3 Places to Find High Yields
Things are finally turning around for income investors, and we've found these stocks to help maximize your gains
3 Stocks to Watch on Wednesday: Tesla Motors Inc (TSLA), Agile Therapeutics Inc (AGRX) and Regeneron Pharmaceuticals Inc (REGN)
Tesla Motors (TSLA) dips on a vehicle deliveries miss, Agile Therapeutics (AGRX) tanks on trial results and Regeneron (REGN) suffers a legal defeat.
Think Sanofi SA (ADR) (SNY) Stock When You Think Big Pharma
Sanofi has a rough time during 2016, but after the U.S. presidential election and with several forward-looking decisions, SNY stock is a buy.
Regeneron Pharmaceuticals Inc (REGN) Stock Pops on Mixed Q3 Results
Regeneron Pharmaceuticals Inc (REGN) stock was up on Friday following mixed results in its earnings report for the third quarter of 2016.
PFE Stock: Ignore Pfizer Inc.’s Earnings Miss at Your Own Peril
Pfizer missed on earnings, and PFE stock slipped as a result. But even if you don't own Pfizer, you don't want to ignore what's happening there.
Sanofi SA (ADR) (SNY) Sues Merck & Co., Inc. (MRK) Over Multiple Patent Infringements
Sanofi (SNY) is suing Merck (MRK) for what it claims are several instances of patent infringement connected to its diabetes drug Lantus.
